[go: up one dir, main page]

MX2019009305A - Oligonucleotido de cadena simple. - Google Patents

Oligonucleotido de cadena simple.

Info

Publication number
MX2019009305A
MX2019009305A MX2019009305A MX2019009305A MX2019009305A MX 2019009305 A MX2019009305 A MX 2019009305A MX 2019009305 A MX2019009305 A MX 2019009305A MX 2019009305 A MX2019009305 A MX 2019009305A MX 2019009305 A MX2019009305 A MX 2019009305A
Authority
MX
Mexico
Prior art keywords
nucleotide
nucleotide sequence
stranded oligonucleotide
oligonucleotide
hybridize
Prior art date
Application number
MX2019009305A
Other languages
English (en)
Inventor
Nakajima Hiroyuki
Iriyama Yusuke
KANAKI Tatsuro
Niwa Masatoshi
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63040892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019009305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of MX2019009305A publication Critical patent/MX2019009305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un oligonucleotido de cadena simple que puede controlar un gen objetivo con alta eficiencia y puede producirse facilmente; es un oligonucleotido de cadena simple representado por la Formula (I), en donde en donde X e Y se hibridan mediante una primera porcion de la secuencia de nucleotidos y una segunda porcion de la secuencia de nucleotidos; X esta compuesta de 7 a 100 nucleotidos, contiene al menos un nucleotido modificado, y tiene una primera secuencia de nucleotidos capaz de hibridarse con un segundo oligonucleotido; Y esta compuesta de 4 a 100 nucleotidos, permite la hibridacion con el primer oligonucleotido antes mencionado, y tiene una segunda secuencia de nucleotidos que contiene al menos un ribonucleotido; por lo menos una de las secuencias de nucleotidos X, Xz e Y tiene una secuencia antisentido capaz de hibridarse con un ARN objetivo; al menos uno de L, Lx y Ly es un grupo de enlace que contiene una estructura no nucleotidica.
MX2019009305A 2017-02-06 2018-02-06 Oligonucleotido de cadena simple. MX2019009305A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017019796 2017-02-06
JP2017144822 2017-07-26
PCT/JP2018/004052 WO2018143475A1 (ja) 2017-02-06 2018-02-06 一本鎖オリゴヌクレオチド

Publications (1)

Publication Number Publication Date
MX2019009305A true MX2019009305A (es) 2019-09-19

Family

ID=63040892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009305A MX2019009305A (es) 2017-02-06 2018-02-06 Oligonucleotido de cadena simple.

Country Status (10)

Country Link
US (2) US11572558B2 (es)
EP (1) EP3584319A4 (es)
JP (2) JP7188087B2 (es)
CN (1) CN110337495B (es)
AU (1) AU2018215440B2 (es)
BR (1) BR112019014547A2 (es)
CA (1) CA3052801A1 (es)
MX (1) MX2019009305A (es)
TW (1) TWI830693B (es)
WO (1) WO2018143475A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015164A2 (pt) * 2016-01-26 2018-12-26 Nissan Chemical Corp oligonucleotídeo de fita simples
AU2018307294B2 (en) * 2017-07-26 2025-04-17 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2021153747A1 (ja) 2020-01-31 2021-08-05 株式会社三和化学研究所 Ａｔｎ１のアンチセンスオリゴヌクレオチド
JPWO2021177418A1 (es) 2020-03-04 2021-09-10
CN115461456A (zh) * 2020-05-25 2022-12-09 日产化学株式会社 可切断的dna编码化文库
WO2024227085A2 (en) * 2023-04-26 2024-10-31 Stoke Therapeutics, Inc. Compounds and methods for treating human subjects
WO2024238385A2 (en) * 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08154687A (ja) 1994-12-12 1996-06-18 Yamanouchi Pharmaceut Co Ltd アンチセンスオリゴヌクレオチド及び抗ウイルス剤
JPH09110894A (ja) 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US20030216335A1 (en) 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
JPH11137260A (ja) * 1997-11-06 1999-05-25 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス環状ダンベル型ｒｎａ−ｄｎａキメラ化合物及び抗インフルエンザウイルス剤
CA2343067A1 (en) 1998-09-21 2000-03-30 Ribozyme Pharmaceuticals, Inc. Hairpin hybridizer molecules for modulation of gene expression
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
CA2526831C (en) 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20070032441A1 (en) 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
JP4383176B2 (ja) 2002-02-13 2009-12-16 武 今西 ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体
AU2003213203A1 (en) 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incorporated Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
AU2003256857A1 (en) * 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
WO2004061081A2 (en) * 2002-12-27 2004-07-22 Ichem Technologies Sirna compounds and methods for the downregulation of gene expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
JP4948163B2 (ja) 2003-05-23 2012-06-06 サーナ・セラピューティクス・インコーポレイテッド 化学修飾した低分子干渉核酸（ｓｉＮＡ）を使用する遺伝子発現のＲＮＡ干渉仲介抑制
KR101137572B1 (ko) * 2003-06-11 2012-05-30 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역조절 올리고뉴클레오티드
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
CA2651042A1 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
ES2603379T3 (es) 2006-10-09 2017-02-27 Roche Innovation Center Copenhagen A/S Compuestos antagonistas de ARN para la modulación de PCSK9
EP3916095A1 (en) 2006-10-18 2021-12-01 Ionis Pharmaceuticals, Inc. Antisense compounds
AU2009273878A1 (en) * 2008-07-25 2010-01-28 Alnylam Pharmaceuticals, Inc. Enhancement of siRNA silencing activity using universal bases or mismatches in the sense strand
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
WO2011052436A1 (ja) 2009-10-29 2011-05-05 国立大学法人大阪大学 架橋型人工ヌクレオシドおよびヌクレオチド
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
DK2558578T3 (en) * 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
KR101894702B1 (ko) 2010-08-03 2018-09-04 가부시키가이샤 보낙 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
WO2013040429A1 (en) 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
WO2013073576A1 (ja) 2011-11-16 2013-05-23 公立大学法人大阪市立大学 RNAi分子の活性を抑制するための核酸分子
CN112386605A (zh) 2011-12-16 2021-02-23 国立大学法人东京医科齿科大学 嵌合的双链核酸
CN104039961A (zh) 2012-01-07 2014-09-10 株式会社博纳克 具有氨基酸骨架的单链核酸分子
CN104271742B (zh) 2012-03-04 2018-06-05 株式会社博纳克 微小rna抑制剂
WO2014043544A1 (en) * 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
SG10201906382QA (en) 2013-05-01 2019-08-27 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv and ttr expression
CN105264073A (zh) 2013-05-30 2016-01-20 国立大学法人东京医科齿科大学 用于递送治疗性寡核苷酸的双链剂
BR112016014986A2 (pt) * 2013-12-27 2018-01-23 Bonac Corporation mirna tipo correspondência artificial, composição e método para suprimir expressão de um gene alvo, composição farmacêutica, método para tratar uma doença, e, ácido nucleico de fita única
WO2015105083A1 (ja) 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
WO2015113922A1 (en) * 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
RU2740032C2 (ru) 2014-12-27 2020-12-30 Бонак Корпорейшн ВСТРЕЧАЮЩИЕСЯ В ПРИРОДЕ миРНК ДЛЯ КОНТРОЛИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ И ИХ ПРИМЕНЕНИЕ
WO2016152352A1 (ja) * 2015-03-20 2016-09-29 国立大学法人名古屋大学 メラノーマ特異的バイオマーカー及びその利用
BR112018015164A2 (pt) 2016-01-26 2018-12-26 Nissan Chemical Corp oligonucleotídeo de fita simples
JP6297079B2 (ja) 2016-02-16 2018-03-20 株式会社Fts フィラーパイプ

Also Published As

Publication number Publication date
EP3584319A1 (en) 2019-12-25
JPWO2018143475A1 (ja) 2019-12-12
JP2023025156A (ja) 2023-02-21
CN110337495A (zh) 2019-10-15
WO2018143475A1 (ja) 2018-08-09
CA3052801A1 (en) 2018-08-09
BR112019014547A2 (pt) 2020-02-18
TW201840848A (zh) 2018-11-16
EP3584319A4 (en) 2021-04-14
US20240084296A1 (en) 2024-03-14
TWI830693B (zh) 2024-02-01
US20210254055A1 (en) 2021-08-19
CN110337495B (zh) 2024-03-29
JP7188087B2 (ja) 2022-12-13
JP7601080B2 (ja) 2024-12-17
AU2018215440B2 (en) 2024-10-24
US11572558B2 (en) 2023-02-07
AU2018215440A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2019009305A (es) Oligonucleotido de cadena simple.
MX2023002818A (es) Oligonucleotido de cadena simple.
EP2580355A4 (en) A REVERSE TRANSCRIPTION AND THROUGH BASE-SPACING RESTRICTED QUANTITATIVE PCR PROVIDED THROUGH AN OLIGONUCLEOTIDE WITH A CHANGED HAIR NEEDLE STRUCTURE
MX2010004984A (es) Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos.
EP4455285A3 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
Allen et al. Circular concatemers of ultra-short DNA segments produce regulatory RNAs
NZ595955A (en) Oligonucleotide comprising an inosine for treating dmd
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
JP2015142558A5 (es)
IN2013MN00522A (es)
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
JP2017002079A5 (es)
MX2024001181A (es) Oligomeros antisentido y metodos de uso de los mismos para el tratamiento de enfermedades asociadas con el gen alfa-glucosidasa acida.
WO2008115632A3 (en) Method for recombining dna sequences and compositions related thereto
EP4328322A3 (en) Probe library construction
HK1221978A1 (zh) Tmprss6 irna组合物及其使用方法
MX2010004452A (es) Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico.
AU2003294440A8 (en) Methods for using riboprimers for strand displacement replication of target sequences
IN2014DN07878A (es)
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
JP2016528887A5 (es)
MX2011007693A (es) Metodos para amplificar acidos nucleicos del virus de hepatitis c.
MX2011009597A (es) Deteccion mejorada de la expresion del gen.
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
US20180251830A1 (en) Dumbbell- pcr: a method to quantify specific small rna variants with a single nucleotide resolution at terminal sequences